{
    "clinical_study": {
        "@rank": "18555", 
        "brief_summary": {
            "textblock": "RATIONALE: The use of endoscopy to place a metal stent in the large intestine is less\n      invasive than surgery for treating cancer-related bowel obstruction and may have fewer side\n      effects and improve recovery.\n\n      PURPOSE: Phase I/II trial to study the effectiveness of endoscopic placement of a metal\n      stent in treating patients who have cancer-related bowel obstruction."
        }, 
        "brief_title": "Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Colorectal Cancer", 
            "Constipation, Impaction, and Bowel Obstruction", 
            "Gastric Cancer", 
            "Gastrointestinal Carcinoid Tumor", 
            "Gastrointestinal Stromal Tumor", 
            "Quality of Life", 
            "Small Intestine Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoid Tumor", 
                "Colorectal Neoplasms", 
                "Constipation", 
                "Fecal Impaction", 
                "Intestinal Obstruction", 
                "Stomach Neoplasms", 
                "Duodenal Neoplasms", 
                "Ileal Neoplasms", 
                "Jejunal Neoplasms", 
                "Malignant Carcinoid Syndrome", 
                "Gastrointestinal Neoplasms", 
                "Gastrointestinal Stromal Tumors", 
                "Intestinal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the objective response and clinical outcome in patients with colonic\n           obstruction secondary to malignancy treated with enteral Wallstents.\n\n        -  Evaluate the efficacy and safety of this treatment in these patients.\n\n        -  Evaluate the quality of life of these patients after enteral Wallstent placement.\n\n      OUTLINE: All patient undergo a colonoscopy, followed by placement of an enteral Wallstent\n      through an endoscope under fluoroscopic guidance into the large intestine.\n\n      Quality of life is assessed at 48 hours and 6 months after the procedure.\n\n      Patients are followed at 48 hours, 30 days, 6 months, and then yearly thereafter until\n      death.\n\n      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Endoscopically confirmed localized tumor as the cause of colonic obstruction\n\n               -  All primary tumor types are eligible\n\n          -  No prior colonic Wallstents\n\n          -  Must have symptoms of gastrointestinal obstruction, including:\n\n               -  Inability to move bowels, absence of flatus, nausea/vomiting, abdominal pain, or\n                  diarrhea\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-3\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Platelet count greater than 50,000/mm^3\n\n        Hepatic:\n\n          -  INR no greater than 1.5 times upper limit of normal\n\n        Renal:\n\n          -  Not specified\n\n        Cardiovascular:\n\n          -  No cardiac condition\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No significant active infection (e.g., pneumonia, peritonitis, wound abscess) that\n             would preclude endoscopy\n\n          -  No other serious concurrent illness\n\n          -  No uncontrolled metabolic disease (e.g., diabetes or hypothyroidism)\n\n          -  No dementia, psychiatric disorder, or altered mental status that would preclude\n             compliance\n\n          -  History of other neoplastic disease allowed\n\n          -  Veterans Administration patients are not eligible\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  Prior or concurrent chemotherapy allowed\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Prior or concurrent radiotherapy allowed\n\n        Surgery:\n\n          -  At least 3 weeks since prior surgery and recovered"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 7, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004911", 
            "org_study_id": "NU 98CC3", 
            "secondary_id": [
                "NU-98CC3", 
                "NCI-G00-1704"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "bowel obstruction management", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage I colon cancer", 
            "stage II colon cancer", 
            "stage III colon cancer", 
            "stage IV colon cancer", 
            "stage I gastric cancer", 
            "stage II gastric cancer", 
            "stage III gastric cancer", 
            "stage IV gastric cancer", 
            "recurrent gastric cancer", 
            "stage I rectal cancer", 
            "stage II rectal cancer", 
            "stage III rectal cancer", 
            "stage IV rectal cancer", 
            "recurrent colon cancer", 
            "recurrent rectal cancer", 
            "localized gastrointestinal carcinoid tumor", 
            "regional gastrointestinal carcinoid tumor", 
            "metastatic gastrointestinal carcinoid tumor", 
            "recurrent gastrointestinal carcinoid tumor", 
            "small intestine adenocarcinoma", 
            "small intestine lymphoma", 
            "small intestine leiomyosarcoma", 
            "recurrent small intestine cancer", 
            "constipation, impaction, and bowel obstruction", 
            "quality of life", 
            "gastrointestinal stromal tumor"
        ], 
        "lastchanged_date": "May 31, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611-3013"
                }, 
                "name": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy", 
        "overall_official": {
            "affiliation": "Robert H. Lurie Cancer Center", 
            "last_name": "Willis G. Parsons, MD, PC", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004911"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Northwestern University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Robert H. Lurie Comprehensive Cancer Center, Northwestern University": "41.878 -87.63"
    }
}